Thiamet G as a Potential Treatment for Polycystic Kidney Disease

• Published in: In vivo (Athens) 2023-11, Vol.37 (6), p.2524-2532
• Main Authors: SU, WEN-CHENG, HUNG, CHI-FENG, WANG, YI-CHIEH, PENG, HUBERT, HUANG, WEN-HUNG, LO, YI-LUN, LO, YUN-HWA, CHEN, YI-CHENG, SU, HSIN-HUI, CHEN, YUNG-LIANG
• Format: Article
• Language: English
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.13360

BACKGROUND/AIMAutosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic disorder primarily caused by mutations in Pkd1 (PC1), which account for the majority of ADPKD cases. These mutations contribute to the formation of cysts in the kidneys and other organs, ultimately leading to renal failure. Unfortunately, there are currently no available preventive treatments for this disease.MATERIALS AND METHODSIn this study, we utilized Pkd1-knockdown mice and cells to investigate the potential involvement of O-GlcNAcylation in the progression of PKD. Additionally, we examined the effects of thiamet G, an inhibitor of O-GlcNAcase (OGA), on PKD mice.RESULTSOur findings indicate that both O-GlcNAcylation and OGT (O-GlcNAc transferase) were downregulated in the renal tissues of Pkd1-silenced mice. Furthermore, O-GlcNAcylation was shown to regulate the stability and function of the C-terminal cytoplasmic tail (CTT) of PC1. Treatment of PKD mice with thiamet G resulted in a reduction of renal cytogenesis in these animals.CONCLUSIONThese results highlight the unique role of O-GlcNAcylation in the development of cyst formation in PKD and propose it as a potential therapeutic target for the treatment of PKD.